← Back to patent-cliff list
Irbesartan/Propagermanium
Tier C — Watch / tradeIrbesartan/Propagermanium
Dimerix Bioscience Pty Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AT1, CCR2
Indications (approved)：局灶性节段性肾小球硬化症, Diabetic nephropathy
Regional status
US
Phase III
2022-05-30
EU
Phase III
2022-05-30
China
Phase III
2022-05-30
Japan
Phase III
2022-05-30
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Irbesartan/Propagermanium?
Approved indications include: 局灶性节段性肾小球硬化症, Diabetic nephropathy.
When does the Irbesartan/Propagermanium patent expire?
No public expiry year is available for Irbesartan/Propagermanium yet; this page updates once verified.
How do I get a quote for Irbesartan/Propagermanium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05